VA's Only Drug for Treatment-Resistant Depression Requires Up to 50 Visits a Year

What's Happening

• •The VA has approved Spravato as a treatment for veterans with treatment-resistant depression.
• •Veterans may need to visit a VA facility up to 50 times a year to receive this treatment.
• •Not all VA facilities offer Spravato, limiting access for some veterans.

Why It Matters

Access to effective mental health treatment is crucial for veterans, especially those struggling with treatment-resistant depression. The logistical challenges posed by the requirement for frequent visits can significantly impact their ability to receive necessary care, potentially worsening their mental health conditions.

What Changes Now

• •Veterans must now plan for up to 50 visits a year to receive Spravato treatment. This requires careful scheduling and consideration of travel logistics, particularly for those living far from VA facilities.
• •Access to Spravato may be limited based on facility availability, meaning some veterans could face delays in starting treatment. It is essential for veterans to check with their local VA to confirm if Spravato is offered.
• •Veterans should consult their healthcare providers to discuss the implications of this treatment requirement. This conversation will help them understand their options and necessary steps moving forward.

What to Watch

• •Monitor announcements from the VA regarding the expansion of Spravato treatment options. This could affect where veterans can receive care and how accessible it becomes.
• •Keep an eye on potential changes to travel assistance programs for veterans needing to visit VA facilities for Spravato. Such changes could alleviate some logistical burdens.
• •Watch for advocacy efforts aimed at improving access to mental health treatments for veterans. These efforts may lead to policy changes that could benefit many service members.

Get the Daily Briefing

Military and veteran news that actually affects you, in your inbox each morning.

More Context

• •Understanding Spravato and Its Requirements: Spravato, a nasal spray medication, is specifically designed for individuals who have not found relief from traditional antidepressants. The treatment protocol requires administration under supervision, which is why veterans must attend a VA facility multiple times throughout the year. This can pose significant challenges for those who live far from a facility or have mobility issues.
• •Impact on Veterans' Access to Care: The requirement for up to 50 visits a year can create barriers for veterans, particularly those in rural areas or with limited transportation options. For example, veterans in remote locations may need to travel long distances, which can be both time-consuming and financially burdensome. This situation could lead to some veterans forgoing necessary treatment altogether.
• •Who is Affected by These Changes?: Veterans diagnosed with treatment-resistant depression, particularly those in the E-4 to E-6 rank range, may find themselves disproportionately affected by the logistical demands of Spravato treatment. Additionally, those with service-connected mental health conditions may be prioritized for this medication, but the travel and time commitments could deter them from pursuing this option.
• •What Changes Now for Veterans Seeking Treatment?: Veterans interested in Spravato need to consult their healthcare provider to determine eligibility and discuss treatment plans. This includes understanding the frequency of visits required and the nearest available VA facility that offers Spravato. Veterans should also prepare for potential travel costs and time away from work or family responsibilities.
• •What to Watch Moving Forward: Veterans should keep an eye on any announcements from the VA regarding expansion of Spravato availability to more facilities. Additionally, updates on potential changes to the treatment protocol or funding for travel assistance may emerge in the coming months. Advocacy groups may also push for policy changes to improve access to this critical treatment.